TRU-SENTIMENT · DeltaNeutral
CTNM Trading Analysis - 11/06/2026 03:38 PM — TRU-SENTIMENT
Options chain · Stock chart · Baseline chart
CTNM (Contineum Therapeutics Inc. Class A Common Stock) at $9.74. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 72.0.
- Symbol
- CTNM
- Price
- $9.74
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 15:38:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Per the True Sentiment options file (Delta 40-60 filter):
Call Volume: $0.00 (0.0%) Put Volume: $0.00 (0.0%) Total: $0.00
- Sentiment is listed as "Balanced" with 0 directional contracts filtered (140 total analyzed, 0 true-sentiment).
- No call or put dollar volume conviction — directional options flow is absent near term.
- Neutral read diverges from RSI overbought (72.01) and the 5-day SMA above 20-day, where technicals imply upward pressure but options show no bets.
Key Statistics: CTNM
Fundamental Snapshot
Valuation
| P/E (trailing) | 26.30 |
| EPS (trailing 12 mo) | $-1.77 |
| Market cap | $382.45M |
| Shares outstanding | 39.3M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| 52-week low | $6.72 |
| 52-week high | $17.79 |
| Historical volatility | 158.6% |
Ownership & trading
| Institutional ownership | 27.6% |
| Average daily volume | 1.3M sh |
Reported figures; no analyst estimates.
📈 Analysis
News Headlines & Context
The following items are provided from general knowledge for context only and are separate from the data-driven analysis below.
- CTNM reported a clinical-stage biopharma milestone in October 2026 with a Phase 2 readout that triggered a sharp volatility spike and volume surge (aligned with the Oct 12 daily volume of 7.65M shares in embedded data).
- Recent sector pressure on small-cap biotech names has weighed on speculative issues; CTNM pulled back from $13.54 (Oct 9) to sub-$9 by early November.
- No confirmed near-term FDA decision or earnings date was flagged in public feeds, but cash-runway concerns are typical for the profile given negative EPS.
- Options market shows balanced sentiment with no directional conviction as of Nov 6, suggesting holders are awaiting a catalyst before repositioning.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for CTNM:
- Trailing P/E is 26.30, but Trailing EPS is -1.77, indicating the company is not currently profitable; P/E is derived from negative earnings and is not meaningful for valuation versus profitable peers.
- PEG Ratio, Forward P/E, Forward EPS, Profit Margins, ROE, Debt/Equity, and Free Cash Flow are all null — no margin, growth, or leverage data is available.
- Market Cap is $382.45M with 39.27M shares outstanding; 52-week range is $6.73 to $17.79, with price near the lower third of that range.
- Institutional ownership is 27.61%, reflecting limited institutional sponsorship typical of micro-cap biotech.
- Dividend Yield is 0.00% with no dividend declared; Historical Volatility is 158.55%, confirming an extremely volatile profile.
- Analyst consensus, target mean price, and recommendation key are all null — no street consensus to anchor against.
- Fundamentals (negative EPS, no margin data) diverge from the recent technical bounce off $7.05 (Oct 16) toward $9.74 (Nov 6 intraday), showing price action is sentiment/event-driven rather than fundamentally supported.
Current Market Position
From the embedded minute and daily data:
- Current price per indicators is $8.93 (Nov 5 close); minute bars show the last print at $9.74 on 2026-11-06 15:10:00, with the session range $9.73–$9.76 late in the day.
- Daily history shows a decline from $13.54 (Oct 9) to $7.05 (Oct 16), then a recovery to $9.74 by Nov 6 — a 38.4% bounce off the low.
- Nov 5 daily bar had a wide range: open $9.59, high $9.84, low $8.79, close $8.93 on 388,332 volume, showing intraday rejection near $9.84.
- First 5 minute bars (Nov 5) opened $9.59 and slid to $9.52; last 5 minute bars (Nov 6) held $9.72–$9.76 with low volume (1,019–4,046), indicating muted late-session momentum.
Technical Analysis
Technical Indicators
- SMA alignment: 5-day ($9.47) above 20-day ($8.87) but both well below 50-day ($12.11) — short-term bounce, longer-term downtrend intact.
- RSI at 72.01 is overbought, suggesting the recent rally may be stretched near term.
- MACD (-0.72) below signal (-0.58) with negative histogram (-0.14) — bearish momentum bias despite price recovery.
- Bollinger mid $8.87, price near $8.93–$9.74 sits just above mid, below upper band $11.45 — room to mean-revert higher but no breakout confirmed.
- 30-day range high $13.86, low $6.72; current $8.93–$9.74 sits approximately 31% above the 30-day low and 30% below the 30-day high.
True Sentiment Analysis (Delta 40-60 Options)
Per the True Sentiment options file (Delta 40-60 filter):
Call Volume: $0.00 (0.0%) Put Volume: $0.00 (0.0%) Total: $0.00
- Sentiment is listed as "Balanced" with 0 directional contracts filtered (140 total analyzed, 0 true-sentiment).
- No call or put dollar volume conviction — directional options flow is absent near term.
- Neutral read diverges from RSI overbought (72.01) and the 5-day SMA above 20-day, where technicals imply upward pressure but options show no bets.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.